Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2021 call → NO我们只需要根据提供的文本判断管理层是否描述了“同类业务连续接洽的规模逐步扩大”这一现象。检查管理层是否明确对比了现在与过去的业务规模,并表明这种扩大是真实的、持续的,且处于早期阶段。 在文本中,管理层提到了长期协议(LTA)和客户预付款。例如,Dave Reeder说:“Since our roadshow, we have made progress on our LTAs... we were talking about roughly $2.5 billion of customer prepayments and fund access fees. And today, that number’s a little bit north of $3 billion of commitments from customers with respect to prepayments and access fees.” 这显示了预付款和访问费用的增加,但这是否表明单个协议规模更大?他们还说:“we’ve also continued to make progress on our LTA revenues where we’ve made good progress. We’re north of $20 billion now.” 但这是总金额,没有明确说单个协议规模变大。 管理层还提到:“we’ve signed about 25 long-term customer agreements. We’ve signed even several since the roadshow, which, as you know, was only a month ago. And we’ve added more than $500 million of customer prepayments and access fees that are committed since the roadshow.” 这显示了新协议带来的预付款增加,但并没有明确说这些新协议比以前的协议更大或更长。他们只是说增加了预付款总额。 此外,Tom Caulfield提到:“we are capacity limited, and we are working diligently every day to get new tooling in and get factories ramped and online so that we can produce more wafers for our customers” 这更多是关于产能扩张,而不是关于单个协议规模。 没有明确提到“每个新协议比上一个更大”或“新客户一开始就比老客户更大”之类的表述。他们提到LTA的持续时间“centered up around four years”,但这是平均,没有说现在签的比过去长。 因此,没有证据表明管理层描述了“同类业务连续接洽的规模逐步扩大”这一现象。他们只是报告了更多的预付款和更多的LTA,但未明确对比单个协议的大小。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.